Repressing immunity in autoimmune disease

New England Journal of Medicine

Volumn 374, Issue 21, 2016, Pages 2090-2092

  Bayry, Jagadeesh ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; HLA ANTIGEN CLASS 2; NANOPARTICLE;

ANIMAL; AUTOIMMUNE DISEASES; ENCEPHALOMYELITIS; HUMAN; IMMUNOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; PHYSIOLOGY; REGULATORY T LYMPHOCYTE;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; DIABETES MELLITUS, TYPE 1; ENCEPHALOMYELITIS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MICE; NANOPARTICLES; T-LYMPHOCYTES, REGULATORY;

EID: 84971251133     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1602864     Document Type: Article

References (5)

1. Bacchetta R, Lucarelli B, Sartirana C, et al. Immunological outcome in haploidentical-HSC transplanted patients treated with IL-10-anergized donor T cells. Front Immunol 2014; 5: 16.
2. Clemente-Casares X, Blanco J, Ambalavanan P, et al. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 2016; 530: 434-40.
3. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365: 2067-77.
4. Bluestone JA, Buckner JH, Fitch M, et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci Transl Med 2015; 7: 315ra189.
5. Jin R, Lin B, Li D, Ai H. Superparamagnetic iron oxide nanoparticles for MR imaging and therapy: design considerations and clinical applications. Curr Opin Pharmacol 2014; 18: 18-27.